The costs of COPD;I costi della broncopneumopatia cronica ostruttiva: La fase prospettica dello Studio ICE (Italian Costs for Exacerbations in COPD)

PharmacoEconomics - Italian Research Articles

Volumn 7, Issue 2, 2005, Pages 119-134

  Lucioni, Carlo ^a,g   Donner, C F ^b   De Benedetto, F ^c   Lusuardi, M ^d   Mazzi, S ^a   Paggiaro, P L ^e   Sanguinetti, C M ^f  

^a Wolters Kluwer Health/ADIS International   (Italy)

^b IRCCS   (Italy)

^c UOC di Pneumologia   (Italy)

^d PATHOLOGY UNIT   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f SAN FILIPPO NERI HOSPITAL   (Italy)

^g Wolters Kluwer Health   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CAREGIVER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRODUCTIVITY; QUESTIONNAIRE; RESPIRATORY FAILURE; SMOKING HABIT;

EID: 22644446422     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320542     Document Type: Article

References (34)

1. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease: impact of new treatment options. Pharmacoecomomics 2001; 19 (3): 245-54
2. Murray CJ, Lopez AD. Alternative projection of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-504
3. http://www.goldcopd.com (sito consultato il 5/5/2004)
4. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623-42
5. ISTAT. Indagine multiscopo sulle famiglie. Roma: Istituto Nazionale di Statistica, 1994
6. ISTAT. Annuario Statistico Italiano. Roma: Istituto Nazionale di Statistica, 2001
7. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118 (5): 1278-85
8. Strassels SA, Smith DH, Sullivan SD. The costs of treating COPD in the United States. Chest 2001; 119: 344-52
9. Lucioni C, Donner CF, De Benedetti F, et al. I costi della broncopneumopatia cronica ostruttiva in Italia: presentazione della prima fase dello studio ICE. Pharmacoeconomics-Italian Research Articles 2004; 6 (1): 5-14
10. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76
11. Lucioni C, Mazzi S, Neeser K. Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics-Italian Research Articles 2004; 6 (2): 81-93
12. Ministero della Sanità. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio Sanitario Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996, Supplemento ordinario alla Gazzetta Ufficiale n. 216 del 14 settembre 1996
13. Lucioni C, Garancini MP, Massi-Benedetti M, et al. per conto dell'Advisory Board Italiano dello Studio CODE-2. Il costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Pharmacoeconomics-Italian Research Articles 2000; 2(1): 1-21
14. ISTAT. Annuario Statistico Italiano. Roma: Istituto Nazionale di Statistica, 2003
15. L'Informatore Farmaceutico 2003. Milano: OEMF, 2003
16. Garattini L, Cornago D. Ossigenoterapia a lungo termine: modalità di acquisto e distribuzione in Italia. Economia & Politica del Farmaco 2004; 1 (2): 29-36
17. Valori medi rilevati presso alcuni centri partecipanti allo studio ICE. Dato non pubblicato, disponibile on file.
18. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60: 429-62
19. Koopmanschap MA, Rutten FFH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4 (6): 446-54
20. Koopmanschap MA, Rutten FFH. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 385-93
21. Koopmanschap MA, Rutten FFH, van Ineveld MA, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89
22. Zuccaro P, Pichini S, Mortali C, et al. Fumo e patologie respiratorie: le carte del rischio per broncopneumopatia cronica ostruttiva e tumore al polmone. Roma: Istituto Superiore di Sanità, 2004
23. Mantovani LG, Mannino S, Donner CF, et al. The cost of COPD: results from the SIRIBO (Studio Italiano sulle Riacutizzazioni Infettive delle Bronchiti). Eur Respir J 2002; 20 (Suppl. 38): 125 (plus poster)
24. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123 (3): 784-91
25. Jansson S-A, Andersson F, Borg S, et al. Costs of COPD in Sweden according to Disease Study. Chest 2002; 122 (6): 1994-2002
26. Decramer M, Gosselink R, Troosters T. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10: 417-23
27. Detournay B, Pribil C, Fournier M, et al.; the SCOPE group. The SCOPE Study: health care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 2004; 7 (2): 168-74
28. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118 (5): 1278-85
29. ASSR, Agenzia per i Servizi Sanitari Regionali. Evoluzione della spesa sanitaria dal 1995 al 2001. Monitor 2003; 3: 62-7
30. ASSR, Agenzia per i Servizi Sanitari Regionali. La spesa sanitaria e altri indicatori di salute nei dati OCSE 2003. Monitor 2003; 6: 67-72
31. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97 (Suppl. C): S43-50
32. SPLF. Health management of chronic obstructive pulmonary disease: summary of the recommendations of the French pneumological society (SPLF). Presse Médicale 1997; 36: 225-32
33. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5 pt 2): S77-S121
34. Anthonisen NR, Connett JE, Kiley JP. Effects of smoking intervention and the use of an inhaled anti-cholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272: 1497-505